Canadian real-world study of aripiprazole LAI in schizophrenia



Presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, Miami, Florida, May 29 – June 1, 2018

The first Canadian naturalistic study in patients with schizophrenia has reported high rates of remission rates and low rates of relapse with long-acting aripiprazole over a one-year period (Oluboka et al. ASCP 2018; abstract). Read More

Use of injectable antipsychotics in bipolar I disorder



Comment by Diane McIntosh, BSc Pharmacy, MD, FRCPC – Vancouver, British Columbia

Among the many clinical challenges in the management of bipolar I disorder, the need for effective treatments that maintain symptomatic remission and promote long-term adherence is paramount. Depending on the study population and the methodology employed, up to 60% of patients diagnosed with bipolar disorder do not adhere to treatment recommendations (Colom et al. Bipolar Disord 2005;7(suppl 5):24-31). A recent study reported that patients with bipolar disorder missed doses a mean of three days in the preceding week (Levin et al. J Nerv Ment Dis 2017;205:182-187). Treatment nonadherence is a major risk factor for relapse, readmission to hospital and suicidality (Rascati et al. Psychiatr Serv 2011;62:1032-1040) and is associated with higher rates of work absenteeism and disability (Bagalman et al. J Occup Environ Med 2010;52:478-485). Read More

‘Seduced by significance” – the p-value controversy


The past decade has seen numerous criticisms of statistical methodology in biomedical research, fuelled in part by a ‘reproducibility crisis’ – the concern that many supposedly significant results cannot be replicated. The latest salvo was an editorial recently published in the Journal of the American Medical Association (Ioannidis JPA. JAMA 2018;319:1429-1430). Read More

Comorbidity – a publishing phenomenon


2018Research into comorbidity has expanded exponentially in recent years, with over 55,000 papers published in the medical literature over the past seven years, according to a new analysis of the Web of Science database of biomedical publications (Catala-Lopez et al. PLoS One 2018;13:e0189091). The literature search terms included “comorbidity”, in which there is another medical condition in addition to an index disease; as well as the emerging “multimorbidity”, a more patient-centric term in which no index disease is defined and all conditions are viewed with equal importance. Several neologisms have been coined less successfully, such as “multipathology”, “polymorbidity”, “polipathology”, and “pluripathology”. Read More